Vanda Pharmaceuticals Inc. saw a significant price increase of 33.69%, reaching a 52-week high, amid a broader market decline with the Nasdaq-100 down 0.19% and the S&P 500 down 0.15%.
This surge is attributed to Vanda Pharmaceuticals receiving FDA approval for NEREUS™ (tradipitant), the first new pharmacologic treatment for motion sickness in over 40 years. The approval is expected to significantly enhance patients' quality of life and address the needs of approximately 65 million people in the U.S. suffering from motion sickness, likely driving substantial revenue growth for the company.
The approval of NEREUS™ not only marks a major milestone for Vanda but also positions the company favorably in the biopharmaceutical sector, as it plans to expand the drug's applications to other conditions, further solidifying its market presence.
Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 13.63 USD with a low forecast of 7.50 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 13.63 USD with a low forecast of 7.50 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.690
Low
7.50
Averages
13.63
High
22.00
Current: 7.690
Low
7.50
Averages
13.63
High
22.00
H.C. Wainwright
H.C. Wainwright
maintain
$22
2026-01-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$22
AI Analysis
2026-01-08
maintain
Reason
H.C. Wainwright notes that Vanda Pharmaceuticals announced that it has received a decision letter from the FDA's Center for Drug Evaluation and Research concluding that the supplemental New Drug Application for HETLIOZ - tasimelteon - for the treatment of jet lag disorder cannot be approved in its current form. In the firm's view, the rejection of tasimelteon constitutes only a minor setback and may not mark the end of dialogue over the compound in this indication. Furthermore, Wainwright draws investors' attention to the fact that its valuation assessment did not include any contribution from sales of tasimelteon in treatment of jet lag. Accordingly, the firm reiterates a Buy rating and a price target of $22 on the shares.
H.C. Wainwright
Buy
maintain
$20 -> $22
2026-01-05
Reason
H.C. Wainwright
Price Target
$20 -> $22
2026-01-05
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Vanda Pharmaceuticals to $22 from $20 and keeps a Buy rating on the shares. The firm cites the addition of tradipitant sales into the model following the approval for the treatment of motion sickness for the target boost.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VNDA
Unlock Now
Cantor Fitzgerald
Olivia Brayer
Overweight
maintain
$11
2025-12-31
Reason
Cantor Fitzgerald
Olivia Brayer
Price Target
$11
2025-12-31
maintain
Overweight
Reason
Cantor Fitzgerald analyst Olivia Brayer keeps an Overweight rating on Vanda Pharmaceuticals with an $11 price target after the FDA approved Nereus for the prevention of motion sickness. The motion sickness opportunity could add upside to estimates, but the bigger implication is that the approval could have an "important look-through" for Vanda's GLP-1 nausea program, which begins Phase 3 in 2026, the analyst tells investors in a research note. Cantor views Nereus' label as "fairly broad." Vanda has talked about motion sickness as a several hundred million peak sales opportunity, the firm adds.
B. Riley
B. Riley
Buy
maintain
$11 -> $14
2025-12-31
Reason
B. Riley
B. Riley
Price Target
$11 -> $14
2025-12-31
maintain
Buy
Reason
B. Riley raised the firm's price target on Vanda Pharmaceuticals to $14 from $11 and keeps a Buy rating on the shares after the FDA approved Nereus for prevention of vomiting induced by motion sickness. The news supports the view that Vanda is an "ongoing turnaround story" trading at an "excessive discount" heading into two more potential approvals within the next 12 months, the analyst tells investors in a research note. Riley says that while the approval could unlock over $100M in peak revenue, the greater significance is in the implications for tradipitant approval in GLP-1 related nausea.
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
